Skip to content
    Real-World Studies

    Dual De-Escalation of Axillary Staging and Radiation in Early Breast Cancer Remains Rare

    Brokaw et alBreast Cancer Research and Treatment

    Dual De-Escalation of Axillary Staging and Radiation in Early Breast Cancer Remains Rare
    A National Cancer Database analysis evaluated national practice patterns and factors associated with the dual de-escalation of axillary staging and adjuvant radiation in early-stage breast cancer. The study identified 316,324 women aged 50 to 69 years with clinical T1–T2N0 HR+/HER2-negative breast cancer who underwent upfront breast-conserving surgery between 2012 and 2022. Patients were categorized by axillary surgery status and adjuvant radiation modality, categorized as whole-breast irradiation (WBI), accelerated partial breast irradiation (APBI), or omission of radiation.
    Overall, 98% of patients underwent sentinel lymph node biopsy (SLNB). Among patients receiving SLNB, 83% were treated with WBI, 11% with APBI, and 6% received no radiation. In contrast, among the subset in whom SLNB was omitted, 63% received WBI, 8% received APBI, and 30% received no adjuvant radiation. Over the study interval, SLNB omission remained low at < 3%, whereas APBI utilization expanded from 8% to 16.5%. Simultaneous dual de-escalation involving both SLNB omission and APBI was rarely performed, persisting at < 0.30% throughout the entire period.
    Shared factors associated with treatment de-escalation included cT1 tumors, ductal histology, low tumor grade, and care received at academic or research programs. Because oncologic safety data for concurrent de-escalation have not been evaluated except in patients aged 70 years and older, the findings highlight the need for prospective studies to define safety, outcomes, and patient selection criteria, with patient-centered discussions guiding management in low-risk cohorts.

    Key Takeaways

    • Dual de-escalation combining sentinel lymph node biopsy omission and accelerated partial breast irradiation occurred in < 0.30% of women aged 50–69 years with clinical T1–T2N0 HR+/HER2-negative breast cancer between 2012 and 2022.
    • Across 316,324 patients, sentinel lymph node biopsy omission remained at < 3% over the study interval, while accelerated partial breast irradiation utilization rose from 8% to 16.5%.
    • Shared predictors associated with de-escalation included cT1 disease stage, ductal histology, low histologic grade, and treatment at academic or research programs.
    Read the original sourceBreast Cancer Research and Treatment